ADHD and Life Expectancy: What the UK Cohort and Barkley Data Actually Show

Why This Conversation Has to Happen

The mortality data on ADHD have been accumulating for two decades, but until recently they have lived in academic journals and patient-organization newsletters rather than in mainstream clinical conversation. That is changing. The 2025 UCL/Cambridge paper using UK primary care records put hard numbers on a phenomenon that pediatricians, psychiatrists, and parents have been observing for a long time: ADHD, untreated and unmanaged across a life course, is associated with a substantially shortened life.

This article reviews the major evidence — the UK cohort, the Barkley actuarial estimates, the Swedish registry data on medication and mortality — and explains what the findings mean for patients and parents. It does not aim to alarm. Mortality data are most useful when they are translated into action, and the action implications of these findings are concrete and largely already established in clinical practice for those who know to look for them.

This article is also a companion to the broader pillar resource on adverse outcomes of untreated ADHD, which covers suicide, substance use, accidents, and academic failure in greater detail. Together, the two resources represent the case for treating ADHD seriously as a public health priority, not as a behavioral nuisance.

The UK Matched Cohort Study: What It Found

The headline 2025 paper is: Life expectancy and years of life lost for adults with diagnosed ADHD in the UK: matched cohort study. British Journal of Psychiatry. 2025.

The investigators used UK primary care electronic health records, matching adults with diagnosed ADHD to controls without ADHD on age, sex, and primary care practice. The matched design controls for some sources of confounding that observational studies otherwise struggle with, particularly geographic and primary care access factors.

The results, expressed as life expectancy at adult diagnosis:

Several features of this analysis are worth noting.

First, the sample is adults with diagnosed ADHD — meaning these are people who reached an adult clinical evaluation and received a diagnosis. ADHD is substantially underdiagnosed in adults, particularly in women, and the cohort therefore reflects a subset of the true ADHD population in the United Kingdom. Whether the life expectancy estimates would be larger or smaller in undiagnosed populations is uncertain, but the direction of the bias is toward a more medically engaged group, which would tend to reduce the observed gap rather than inflate it.

Second, the gap for women is larger than for men in absolute years. This is consistent with broader literature showing that ADHD is diagnosed later in women, is more frequently comorbid with anxiety and mood disorders, and is associated with delays in receiving appropriate treatment. The pattern is also covered in the dedicated resource on ADHD in women.

Third, this is a population-level finding. Individual mortality risk varies enormously based on treatment status, comorbidities, behavioral risk factors, and socioeconomic context. The headline numbers should be read as a population estimate of the consequences of ADHD as currently treated in the UK system — not as a forecast for any individual.

The Barkley Life Expectancy Work

The Barkley estimates predate the UK study by several years and use a different methodology. Russell Barkley and Mariellen Fischer published actuarial life expectancy analyses based on their decades-long Milwaukee longitudinal study of children with hyperactive child syndrome followed into adulthood.

The headline paper is: Barkley RA, Fischer M. Hyperactive Child Syndrome and Estimated Life Expectancy at Young Adult Follow-Up: The Role of ADHD Persistence and Other Potential Predictors. Journal of Attention Disorders. 2019. PMID 30526189.

The methodology used 14 variables related to disability, health, and lifestyle entered into the University of Connecticut Goldenson Center for Actuarial Research life expectancy calculator. The variables were measured directly in the longitudinal cohort at adult follow-up. The findings:

• Childhood ADHD combined-type was associated with a 9.5-year reduction in healthy life expectancy and an 8.4-year reduction in total life expectancy compared with control children, by adult follow-up.
• Persistence of ADHD into adulthood was associated with a 12.7-year reduction in total life expectancy — a substantially larger effect than non-persistent ADHD.
• The primary actuarial driver was impaired behavioral inhibition, which mapped onto multiple downstream risk behaviors (smoking, accidents, sedentary lifestyle, risky driving, substance use).

The Barkley actuarial method and the UK cohort method are genuinely different approaches. Actuarial estimation predicts life expectancy from measured risk factors using insurance industry models; the matched cohort approach uses observed mortality in two groups. The two approaches converge on a similar magnitude of effect — life expectancy reductions roughly in the 7 to 13 year range, with larger effects for ADHD that persists into adulthood — which is the kind of convergence across methods that strengthens confidence in the underlying finding.

Why the Gap Exists: The Mediators

The crucial conceptual point in this literature: ADHD itself, as a neurodevelopmental condition affecting attention and executive function, does not directly cause cardiovascular disease, cancer, or biological aging. The mortality gap is mediated through behavioral and health-system pathways that ADHD profoundly influences.

The major mediators identified across studies:

The UCL/Cambridge paper investigators noted explicitly that the shortened lifespan is "not because of the condition itself, but may be due to co-occurring health conditions, unmet medical needs, and modifiable risk factors, like smoking tobacco and substance misuse."

This is the most clinically important framing of the entire literature: the mediators are modifiable, and they are exactly the targets that good treatment of ADHD and its comorbidities addresses.

The Swedish Mortality Data: Medication Reduces Risk

Among the most important findings in the entire ADHD mortality literature is the Swedish national registry work demonstrating that pharmacological treatment of ADHD reduces all-cause mortality.

The Swedish health system maintains comprehensive registries linking medical diagnoses, prescription dispensing, and death records for the entire national population. This infrastructure has enabled some of the strongest pharmacoepidemiologic studies in psychiatry, using designs that control for within-person confounding by comparing the same individual's on-medication and off-medication periods.

The headline finding from this body of work: ADHD pharmacological treatment is associated with approximately a 19 percent reduction in all-cause mortality, with the strongest effects on unnatural deaths (accidents, suicide, substance-related deaths).

This finding is mechanistically coherent. The medications used to treat ADHD — primarily stimulants, with non-stimulant options including atomoxetine and viloxazine — improve attention, reduce impulsivity, and improve self-regulation. The mortality mediators identified above (accidents, suicide, substance use) are precisely the outcomes one would expect to improve when attention and impulse control improve. The Swedish data show this is not theoretical; it is observable in population-scale mortality records.

The Swedish findings are also covered in the dedicated pillar on ADHD pharmacology and natural course, which describes the broader functional outcomes associated with treatment, including reductions in criminal convictions and motor vehicle accidents.

What This Means for Treatment Urgency

The clinical implication of these data is direct: the decision to evaluate and treat ADHD is not a quality-of-life decision. It is a health-protective decision with population-scale mortality implications. This frame matters because many adults and parents weigh ADHD evaluation and treatment against vague worries about medication safety or stigma, without weighing the alternative — the mortality and morbidity associated with untreated ADHD.

The reframe is straightforward. The relevant comparison is not "ADHD medication versus no medication." It is "treated ADHD versus untreated ADHD," where untreated ADHD carries the mortality profile described above. The first comparison favors caution; the second favors action.

This is not a marketing pitch for stimulants. The cardiovascular safety of ADHD medications has been studied extensively in large cohorts, and the cardiovascular risks are small in appropriately screened populations. The mortality data are far larger in the untreated direction than in the treated direction. The risk-benefit calculus is clear.

It also reframes the conversation with parents who are uncertain about treating a child's ADHD. Untreated childhood ADHD is associated with elevated risk for adolescent substance use, motor vehicle accidents, suicide attempts, expulsion, and academic failure — all of which compound into the adult outcomes that drive the life expectancy gap. The decision to wait, "see how it goes," or try only behavioral interventions has costs that the mortality literature has now quantified.

Where Heterogeneity Comes In

One important nuance: the life expectancy estimates are population averages, and ADHD is not a single condition with a single risk profile. The recent neuroimaging work identifying three distinct ADHD biotypes is one expression of this heterogeneity. Different presentations of ADHD likely have different mortality risk profiles. ADHD with prominent emotional dysregulation and severe combined symptoms may carry different risks than predominantly inattentive ADHD without significant impulsivity.

The clinical implication: the life expectancy data establish a population-level signal that motivates evaluation and treatment. The individual risk profile for a specific patient depends on their symptom severity, persistence, comorbidities, treatment status, and behavioral context. That individual assessment is what a careful clinical evaluation should produce.

What to Do Today

If You Have or Suspect ADHD

1. Get evaluated, or get re-engaged if you have been out of treatment. A structured evaluation by a clinician trained in ADHD remains the diagnostic standard. If you have a diagnosis but are not currently in treatment, the mortality data make a strong case for re-engagement.
2. If indicated, treat with medication. The Swedish mortality reduction of approximately 19 percent is a population effect of medication use. For individuals with significant symptom burden and impairment, the clinical case for pharmacological treatment rests on functional outcomes, but the mortality signal is real and reinforces the clinical case. The pharmacology pillar covers medication evidence in detail.
3. Treat comorbid conditions actively. Depression, anxiety, and substance use disorders are major mediators of the mortality gap. They are also commonly under-recognized in ADHD because the executive function symptoms can mask or be confused with mood and anxiety presentations. Active screening and treatment is high-yield.
4. Manage modifiable cardiovascular risk factors. Smoking, sleep, exercise, weight, primary care engagement. These are the same targets every adult is supposed to manage, but they are systematically under-managed in untreated ADHD. The opportunity here is unusually large.
5. Drive carefully and use safety equipment. Motor vehicle accidents are one of the most consistent mediators of the mortality gap in ADHD. Medication reduces this risk substantially. Safety behaviors — seat belts, helmets, attention to fatigue and substance use — are non-negotiable.

If You Are a Parent of a Child with ADHD

1. Treat the ADHD. The decision to delay or avoid treatment carries costs the mortality data now quantify. The decision to treat carries small and well-characterized medication risks. The calculus favors treatment when symptoms cause functional impairment.
2. Maintain primary care engagement and developmental monitoring. Children with ADHD benefit from continuity of pediatric care, particularly through the high-risk adolescent transition. The adolescent years are when accident, substance use, and self-harm risks emerge most prominently.
3. Address sleep, screen time, and physical activity actively. These are environmental factors that compound or attenuate ADHD-related risk behaviors.
4. Plan for the transition to adult care. ADHD persists into adulthood in roughly half of cases, and the transition from pediatric to adult care is a point at which many patients fall out of treatment. This transition is one of the most consequential moments in the lifespan for ADHD outcomes.

The Bottom Line

The 2025 UK matched cohort study put a number on what clinicians have observed for decades: adults with ADHD lose meaningful years of life on average. The Barkley actuarial work, using different methods, converges on a similar magnitude. The Swedish mortality data show that medication treatment reduces this risk by approximately 19 percent. The mortality gap is mediated by accidents, suicide, substance use, cardiovascular risk, and unmet care — all of which are modifiable, and all of which are targets of competent ADHD treatment.

The data are not destiny. They describe what happens when ADHD is undiagnosed, untreated, or undertreated at population scale. They describe a clinical opportunity, not a clinical inevitability. Treated ADHD with attention to comorbidities and modifiable risk factors looks very different from the population averages reported in the cohort studies.

The clinical message is that ADHD warrants the same treatment urgency as any other chronic condition with established mortality risk. It is treatable. The pharmacology is well-characterized. The functional benefits are large. The mortality reductions associated with treatment are real. And the cost of waiting — for parents weighing whether to evaluate a child, or adults wondering whether their long-standing attention and impulsivity patterns warrant clinical attention — is no longer abstract.

Frequently Asked Questions

Does ADHD shorten your life?

Yes, on average. The 2025 UCL/Cambridge BJPsych matched cohort study found that men with diagnosed ADHD lose approximately 6.78 years of life and women lose 8.64 years compared with matched controls. The Barkley actuarial estimates suggest 8 to 13 years lost depending on persistence. The mortality gap is not caused by ADHD as a brain condition directly — it is mediated by accidents, suicide, substance use, cardiovascular risk, and unmet care.

Why do people with ADHD die earlier?

The major mediators are unintentional injury (especially motor vehicle accidents), suicide and self-harm, substance use disorders, cardiovascular risk behaviors, and unmet medical care needs. Impaired behavioral inhibition — the core ADHD trait — drives most of these downstream pathways.

Does ADHD medication reduce mortality risk?

Yes. Swedish national registry data show that pharmacological treatment for ADHD is associated with approximately a 19 percent reduction in all-cause mortality, with the strongest effects on unnatural deaths. This is one of the strongest mortality-reduction findings in psychiatry.

Does the life expectancy estimate apply to everyone with ADHD?

No. The figures are population averages. Individual mortality risk depends on symptom severity, persistence into adulthood, treatment status, comorbidities, behavioral factors, and socioeconomic context. Treatment substantially alters the trajectory.

Is the life expectancy gap a new finding?

The existence of elevated mortality in ADHD has been documented for decades. The 2025 UCL/Cambridge paper is the largest and most rigorous quantification using population health data. It converges with the Barkley actuarial estimates from longitudinal cohort work, which is the kind of cross-method convergence that strengthens confidence in the finding.

What should I do if I have ADHD and just learned about this data?

Treat the ADHD and treat the modifiable mediators. Pharmacological treatment of ADHD is associated with reduced mortality. Treating comorbid depression, anxiety, and substance use is critical. Managing cardiovascular risk factors — smoking, sleep, exercise, weight, and primary care engagement — is unusually high-yield in this population. The estimates are not destiny.

Primary References

Further Reading

• ADHD Brain Scan Subtypes: What the 2026 Research Actually Shows — Companion analysis of the new JAMA Psychiatry and Translational Psychiatry biotype findings
• Adverse Outcomes of Untreated ADHD — Pillar resource: suicide, substance use, accidents, and academic failure in untreated ADHD
• ADHD Pharmacology and Natural Course — Pillar resource: medication evidence, functional outcomes, and the JAMA Psychiatry 2025 Li SCCS study
• The Cost of Untreated ADHD — Economic and personal costs across the lifespan
• Stimulant Medications and Protection from Adverse Outcomes — How ADHD medication treatment improves specific functional outcomes
• ADHD Medications and Cardiovascular Risk — What the large-scale evidence shows about stimulant cardiac safety
• Is ADHD Genetic? — Twin studies, GWAS, and what the heritability data mean for families
• Complete ADHD Guide — Comprehensive resource on ADHD diagnosis, neurobiology, and treatment
• ADHD Psychiatrist NYC — Evaluation and medication management for adults and adolescents with ADHD